查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931244

植入式藥物釋放球囊市場：按適應症、產品類型、藥物類型、最終用戶分類的全球預測（2026-2032年）

Implantable Drug Eluting Balloon Market by Indication, Product Type, Drug Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，植入式藥物釋放型球囊市場價值將達到 12.5 億美元，到 2026 年將成長至 13.4 億美元，到 2032 年將達到 21.3 億美元，複合年成長率為 7.86%。

關鍵市場統計數據
基準年 2025 12.5億美元
預計年份：2026年 13.4億美元
預測年份 2032 21.3億美元
複合年成長率 (%) 7.86%

全面介紹植入式藥物釋放型球囊領域，重點在於臨床證據、技術成熟度和不斷變化的相關人員優先事項。

生物相容性藥物釋放型球囊技術處於介入治療創新與不斷變化的臨床需求的交匯點，它提供了一種結合機械擴張和局部藥物控制內膜增生的遞送平台。近年來，臨床醫生對永久性支架的替代方案越來越感興趣，尤其是在維持血管順應性和最大限度減少異物負荷是臨床首要考慮因素的情況下。隨著技術的成熟，臨床、監管和商業相關人員正在重新評估藥物釋放型球囊與藥物釋放型支架和新興生物可吸收技術相比的作用。

臨床個人化、技術進步與監管如何融合，重新定義藥物釋放型球囊商業化的策略路徑

隨著臨床實務、裝置技術和監管要求的同步發展，植入式藥物釋放型球囊的格局正在改變性變化。臨床治療正朝著個人化血管治療方向顯著轉變，介入醫師會根據病變形態、病患合併症和長期血管保護策略來最佳化器械選擇。這一趨勢有利於那些能夠最大限度減少長期植入負擔並保留未來治療選擇的技術，從而提升了藥物釋放型球囊平台的戰略重要性。

本文分析了2025年關稅將如何重塑整個設備價值鏈的採購、製造在地化和採購策略。

2025年實施的關稅和貿易措施顯著增加了支持植入式藥物釋放型球囊的全球供應鏈的複雜性，影響了供應商的選擇、製造地和籌資策略。關稅帶來的成本壓力迫使製造商重新評估其採購來源，盡可能優先考慮近岸外包和本地生產，以降低跨境關稅風險並縮短前置作業時間。這種轉變不僅影響最終設備的組裝，也影響關鍵零件的採購，例如特殊聚合物、藥物塗層製劑和精密導管組件。

關鍵細分分析將臨床適應症、器材類型、藥理學和臨床環境與策略發展和商業化選擇連結起來。

基於細分市場的洞察揭示了臨床應用案例、產品設計、藥物以及醫療環境如何共同影響藥物釋放型球囊的開發和商業化策略。根據適應症，市場可分為新興病變和支架內再血管再阻塞，其中新發病變可細分為冠狀動脈疾病和周邊動脈疾病。冠狀動脈疾病進一步分為急性病變和慢性完全閉塞，而周邊動脈疾病則分為膝下和股膕動脈區域。這些臨床差異導致了不同的設計重點：冠狀動脈應用需要超低輪廓、高順應性的導管，以便在複雜的血管解剖結構中進行短時擴張；而外周動脈應用則傾向於優先考慮更長的球囊長度、更高的標稱壓力和更強的藥物滯留能力，以適應不同的血管壁生物學特性。

區域趨勢和差異化的准入策略將影響全球醫療保健生態系統的採納路徑和商業化重點。

區域趨勢對植入式藥物釋放型球囊的臨床應用、監管路徑和商業性需求有顯著影響。在美洲，介入性心臟病學基礎設施的投資、完善的導管介入手術報銷機制以及冠狀動脈介入治療的高普及率，共同營造了一種環境，使得冠狀動脈應用成為優先考慮的領域，支付方和綜合醫療網路對臨床證據進行嚴格審查。該地區日益重視進行嚴謹的隨機對照試驗和真實世界證據研究，以證明其具有可比較的臨床療效和成本效益，從而支持更廣泛的應用。

策略競爭動態揭示了技術差異化、臨床證據和供應鏈韌性如何塑造藥物釋放型球囊領域的領導地位。

藥物釋放型球囊領域的競爭主要集中在技術差異化、臨床證據產生和供應鏈韌性。領先的研發企業正致力於改進載體化學和塗層均勻性，以最佳化短時間內藥物的輸送，同時也投資於導管輸送性和觸覺回饋，這對於複雜病變至關重要。隨著醫療設備製造商權衡自身能力與外包精密塗層和包裝技術之間的利弊，他們與專業契約製造之間的合作也日益普遍。

透過整合臨床療效檢驗、供應鏈多元化和市場進入策略最佳化等切實可行的建議，加速永續應用並提升競爭優勢。

為了加速藥物釋放型球囊的持續應用，產業領導者應採取整合策略，同時兼顧臨床驗證、供應鏈靈活性和客製化市場進入。優先開展以支付方和臨床醫生需求為導向的臨床項目，將創造更具吸引力的價值提案。將終點指標與衛生經濟學相結合的實用性試驗和真實世界證據項目，可以縮短從監管部門核准到常規應用的路徑。同時，企業應考慮生產多元化和區域生產夥伴關係，以降低關稅風險並更好地應對力在地採購趨勢。

我們採用透明、多方面的調查方法，結合與臨床醫生面對面的交談、觀察他們的工作以及嚴格的二次分析，以支持策略決策。

本研究整合了一手和二手資料，對藥物釋放型球囊療法進行了全面且可重複的評估。一級資訊來源包括對介入醫師、採購人員、監管專家和生產合作夥伴的結構化訪談，以及對臨床環境中手術流程和設備操作的觀察分析。這些直接訪談旨在了解影響該療法應用的臨床決策因素和操作限制，同時檢驗關於設備在真實環境中表現的陳述。

在他的策略概述中，他強調，整合臨床、營運和商業合作對於實現藥物釋放型球囊的長期價值至關重要。

總之，植入式藥物釋放型球囊領域正進入一個關鍵階段，技術成熟度、臨床差異化以及策略性供應選擇將決定最終的競爭者。該設備的核心提案在於無需永久植入即可提供局部抗增殖治療，這與臨床醫生對血管保護和靈活治療方案的需求不謀而合。然而，要充分發揮這一提案，需要對臨床證據、設備性能以及能夠適應不同醫療環境和區域市場動態的商業模式進行持續投入。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依適應症分類的植入式藥物輸送球囊市場

  • 新病變
    • 冠狀動脈疾病
    • 周邊動脈疾病
  • 支架內血管再阻塞

第9章 依產品類型植入式藥物釋放球囊市場

  • 冠狀動脈
  • 周邊血管

第10章 依藥物類型植入式藥物噴射球囊市場

  • 紫杉醇
  • Sirolimus

第11章 以最終用戶分類的植入式藥物釋放球囊市場

  • 門診手術中心
  • 心臟中心
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 區域性植入式藥物釋放球囊市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章植入式藥物釋放球囊市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國植入式藥物釋放球囊市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國植入式藥物噴射球囊市場

第16章：中國植入式藥物噴射球囊市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alvimedica Medical Technologies Inc.
  • AngioDynamics, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Concept Medical, Inc.
  • ConMed Corporation
  • Cook Medical Incorporated
  • Eurocor GmbH
  • iVascular SLU
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Opto Circuits（India）Ltd.
  • Paladin Medical Pvt. Ltd.
  • Terumo Corporation
Product Code: MRR-7B550E008DE0

The Implantable Drug Eluting Balloon Market was valued at USD 1.25 billion in 2025 and is projected to grow to USD 1.34 billion in 2026, with a CAGR of 7.86%, reaching USD 2.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.25 billion
Estimated Year [2026] USD 1.34 billion
Forecast Year [2032] USD 2.13 billion
CAGR (%) 7.86%

A comprehensive introduction to the implantable drug eluting balloon field highlighting clinical rationale, technological maturation, and evolving stakeholder priorities

The implantable drug eluting balloon sector sits at the intersection of interventional innovation and evolving clinical needs, offering a delivery platform that combines mechanical dilation with localized pharmacologic inhibition of neointimal proliferation. Recent years have seen growing interest from clinicians seeking alternatives to permanent stents, particularly where preserving vessel compliance and minimizing foreign-body burden are clinical priorities. As the technology matures, stakeholders across clinical, regulatory, and commercial domains are reassessing the role of drug eluting balloons relative to drug-eluting stents and emerging bioresorbable technologies.

Advances in drug formulations, excipient chemistry, and balloon coating techniques have improved drug transfer efficiency during brief inflation windows, while iterative improvements in catheter design have enhanced deliverability in complex anatomies. Clinicians are increasingly differentiating indications by lesion context, such as de novo disease versus in-stent restenosis, and across coronary and peripheral vascular territories. These clinical nuances are shaping both trial design and real-world adoption patterns. Consequently, strategic priorities for manufacturers now extend beyond engineering and clinical validation to encompass supply chain resilience, regulatory engagement, and nuanced payer communications that reflect the distinct value proposition of local drug delivery without permanent implants.

How clinical personalization, technological advances, and regulatory scrutiny are converging to redefine strategic pathways for drug eluting balloon commercialization

Transformative shifts are reshaping the landscape for implantable drug eluting balloons as clinical practice, device technology, and regulatory expectations co-evolve. There is a clear clinical shift toward personalized vascular care, with interventionalists tailoring device selection to lesion morphology, patient comorbidity, and long-term vessel preservation strategies. This trend favors technologies that minimize chronic implant burden and preserve future treatment options, elevating the strategic relevance of drug eluting balloon platforms.

On the technology front, improvements in drug carrier matrices and transfer kinetics are enabling more predictable tissue uptake during short balloon inflation periods, which in turn supports broader use across complex coronary lesions and challenging peripheral anatomies. Concurrently, payer and regulatory scrutiny of clinical endpoints is intensifying, pushing manufacturers to design robust comparative studies that demonstrate meaningful patient-centric benefits such as reduced reintervention rates, improved limb salvage outcomes in peripheral disease, or decreased incidence of late adverse events. The convergence of these forces is prompting manufacturers to adopt integrated development approaches that couple engineering innovation with targeted clinical programs and commercial models that address differentiated end-user needs.

An analytical examination of how 2025 tariff measures are reshaping sourcing, manufacturing localization, and procurement strategies across the device value chain

The imposition of tariffs and trade measures in 2025 has introduced a material layer of complexity for global supply chains supporting implantable drug eluting balloons, influencing sourcing choices, manufacturing footprints, and procurement strategies. Tariff-driven cost pressures have incentivized manufacturers to reassess input sourcing, favoring nearshoring or regional production where feasible to reduce exposure to cross-border duties and to shorten lead times. This reorientation affects not only final device assembly but also the sourcing of critical components such as specialized polymers, coated drug formulations, and precision catheter subassemblies.

Procurement teams within hospital systems and ambulatory centers are reacting by revisiting supplier qualification criteria and total landed cost models rather than relying solely on unit price. In turn, contract negotiations increasingly emphasize supply continuity guarantees, inventory buffers, and collaborative risk-sharing arrangements that mitigate the commercial impact of sudden duty changes. Regulatory interactions have also been influenced, as manufacturers balance the need to maintain consistent device specifications across markets with the operational realities of diversified manufacturing. Ultimately, the cumulative impact of tariffs has accelerated strategic decisions around localization, vertical integration of critical inputs, and contractual mechanisms that stabilize access while preserving clinical quality and device performance.

Key segmentation insights connecting clinical indications, device types, pharmacology, and care settings to strategic development and commercialization choices

Segmentation-driven insights reveal how clinical use cases, product designs, pharmacologic agents, and care settings collectively shape development and commercial strategies for drug eluting balloons. Based on indication, the market divides into de novo lesion and in-stent restenosis, with de novo lesion further differentiated into coronary artery disease and peripheral artery disease. Coronary artery disease is further characterized by acute lesions and chronic total occlusions, while peripheral artery disease splits into below-the-knee and femoropopliteal territories. These clinical distinctions create divergent design priorities: coronary applications demand ultra-low profile, high-trackability catheters calibrated for short inflation times in tortuous anatomy, whereas peripheral use often prioritizes longer balloon lengths, higher nominal pressures, and enhanced drug retention to address different vessel wall biology.

Based on product type, commercial strategies distinguish coronary and peripheral offerings, necessitating separate regulatory evidence packages and sales training models for interventional cardiology versus vascular surgery and interventional radiology audiences. Based on drug type, the choice between paclitaxel and sirolimus influences both clinical positioning and formulation science; paclitaxel's lipophilicity supports rapid tissue uptake while sirolimus and its analogues require advanced carrier systems to achieve effective local delivery, prompting divergent R&D paths. Based on end user, adoption dynamics vary across ambulatory surgical centers, cardiac centers, and hospitals, with hospitals further segmented into private and public institutions; reimbursement pathways, purchasing cycles, and capital allocation norms differ across these settings, shaping go-to-market tactics and education investments. Collectively, these segmentation axes inform trial design, messaging, and supply models that must be aligned to clinical workflows and stakeholder incentives.

Regional dynamics and differentiated access strategies that determine adoption pathways and commercialization priorities across global healthcare ecosystems

Regional dynamics exert a pronounced influence on clinical adoption, regulatory pathways, and commercial imperatives for implantable drug eluting balloons. In the Americas, investment in interventional cardiology infrastructure, established reimbursement frameworks for catheter-based therapies, and a high prevalence of coronary interventions create an environment where coronary applications are prioritized and clinical evidence is closely scrutinized by payers and integrated delivery networks. This region tends to emphasize robust randomized and real-world evidence demonstrating comparative clinical outcomes and cost-effectiveness to support broader uptake.

Across Europe, Middle East & Africa, heterogeneity in regulatory regimes and reimbursement mechanisms requires flexible market-access approaches. Some European markets reward technologies that demonstrate health-economic value and downstream reductions in reintervention, while other jurisdictions adopt more cautious adoption curves driven by national procurement processes. In emerging Middle Eastern and African contexts, infrastructural constraints and differing procedural volumes shape demand toward devices that are cost-effective and operationally resilient. In the Asia-Pacific region, diverse healthcare ecosystems span advanced public-private hospital networks to rapidly growing ambulatory centers; cost sensitivity and volume-driven procurement can favor locally adapted manufacturing strategies, and clinical adoption is accelerated where regulatory pathways support expedited evaluation of devices with clear clinical differentiation. These regional contrasts underscore the need for tailored regulatory, clinical, and commercial roadmaps rather than one-size-fits-all launch strategies.

Strategic competitive dynamics reveal how technological differentiation, clinical evidence, and supply resilience shape leadership in the drug eluting balloon domain

Competitive activity in the drug eluting balloon arena centers on technological differentiation, clinical evidence generation, and supply chain resilience. Leading developers pursue incremental improvements in carrier chemistries and coating uniformity to optimize drug transfer during short inflation windows, while also investing in catheter deliverability and tactile feedback that matters in complex lesions. Partnerships between device manufacturers and specialty contract manufacturers have become common as firms deliberate the trade-offs between in-house capabilities and outsourced expertise for precision coating and packaging.

Clinical trial strategies are a critical axis of competition; companies that design head-to-head or pragmatic comparative studies tailored to payer-relevant endpoints can more effectively articulate value propositions. Strategic monetization approaches vary by firm, with some prioritizing direct hospital relationships and capital sales, while others pursue distributor networks and bundled service offerings that include training, procedural support, and outcomes tracking. Collaboration with key clinical opinion leaders and investment in post-market registries further differentiate players by demonstrating long-term performance across both coronary and peripheral indications. Finally, robustness of quality systems and regulatory alignment across jurisdictions is increasingly decisive, as purchasers place a premium on suppliers that can reliably deliver devices under shifting trade and regulatory conditions.

Actionable recommendations that integrate clinical validation, supply chain diversification, and tailored market access to accelerate durable adoption and competitive advantage

Industry leaders should adopt an integrated strategy that simultaneously addresses clinical proof, supply chain agility, and tailored market access to accelerate sustainable adoption of drug eluting balloons. Prioritizing clinical programs that are designed with payers and clinicians in mind will yield more compelling value narratives; pragmatic trials and real-world evidence initiatives that align endpoints with health-economic relevance can shorten the pathway from regulatory clearance to routine use. At the same time, companies should evaluate manufacturing diversification and regional production partnerships to mitigate tariff exposure and to improve responsiveness to local procurement preferences.

Commercial organizations must invest in differentiated engagement models for coronary and peripheral stakeholders and adapt training and reimbursement support to the specific needs of ambulatory centers, cardiac centers, and both public and private hospitals. Technology roadmaps should emphasize modular innovations that support both paclitaxel and sirolimus-based platforms, enabling portfolio flexibility as clinical preferences evolve. Finally, establishing collaborative procurement frameworks with large health systems and aligning warranty or outcomes-based contracting can create stronger commercial anchors, reduce adoption risk for customers, and enhance long-term uptake across multiple geographies.

A transparent, multi-method research methodology combining primary clinician engagement, operational observation, and rigorous secondary analysis to inform strategic decisions

This research synthesizes primary and secondary intelligence to produce a comprehensive, replicable assessment of the implantable drug eluting balloon landscape. Primary inputs include structured interviews with interventional clinicians, procurement leaders, regulatory specialists, and manufacturing partners, complemented by observational analysis of procedural workflows and device handling in clinical settings. These direct engagements were designed to capture both clinical decision drivers and operational constraints that influence adoption, as well as to validate real-world device performance narratives.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical disclosures related to coatings, drug formulations, and catheter systems. Analytical methods included cross-case synthesis to identify common themes across indications and geographies, scenario analysis to assess the operational impact of trade measures and supply disruptions, and triangulation of qualitative insights with technical literature to ensure consistency. Data integrity measures included cross-validation with multiple expert sources and sensitivity checks on strategic conclusions. The research approach emphasizes transparency, methodological rigor, and practical relevance to support decision-making by clinical leaders, product strategists, and procurement executives.

A strategic concluding synthesis emphasizing the need for integrated clinical, operational, and commercial alignment to realize long-term value in drug eluting balloons

In conclusion, the implantable drug eluting balloon sector is entering a phase where technological refinement, clinical differentiation, and strategic supply choices will determine which players scale successfully. The device's core value proposition-delivering localized antiproliferative therapy without leaving a permanent implant-resonates with clinicians seeking vessel preservation and flexible treatment pathways. However, capitalizing on this proposition requires coordinated investments in clinical evidence, device performance, and commercial models adapted to diverse care settings and regional market dynamics.

As geopolitical and trade dynamics alter the economics of global supply chains, manufacturers that proactively address manufacturing localization, contractual resilience, and end-user education will be better positioned to sustain adoption momentum. The companies that successfully combine rigorous clinical validation with operational agility and payer-focused messaging will create the strongest platform for long-term competitive advantage. Stakeholders should therefore pursue an integrated approach that aligns R&D priorities, regulatory strategy, and commercial execution to realize the full clinical and economic potential of drug eluting balloon technology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Drug Eluting Balloon Market, by Indication

  • 8.1. De Novo Lesion
    • 8.1.1. Coronary Artery Disease
    • 8.1.2. Peripheral Artery Disease
  • 8.2. In-Stent Restenosis

9. Implantable Drug Eluting Balloon Market, by Product Type

  • 9.1. Coronary
  • 9.2. Peripheral

10. Implantable Drug Eluting Balloon Market, by Drug Type

  • 10.1. Paclitaxel
  • 10.2. Sirolimus

11. Implantable Drug Eluting Balloon Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Implantable Drug Eluting Balloon Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Drug Eluting Balloon Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Drug Eluting Balloon Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Drug Eluting Balloon Market

16. China Implantable Drug Eluting Balloon Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alvimedica Medical Technologies Inc.
  • 17.7. AngioDynamics, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. BIOTRONIK SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cardionovum GmbH
  • 17.13. Concept Medical, Inc.
  • 17.14. ConMed Corporation
  • 17.15. Cook Medical Incorporated
  • 17.16. Eurocor GmbH
  • 17.17. iVascular S.L.U.
  • 17.18. Koninklijke Philips N.V.
  • 17.19. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.20. Medtronic plc
  • 17.21. MicroPort Scientific Corporation
  • 17.22. Opto Circuits (India) Ltd.
  • 17.23. Paladin Medical Pvt. Ltd.
  • 17.24. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)